<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195103</url>
  </required_header>
  <id_info>
    <org_study_id>10-000721</org_study_id>
    <nct_id>NCT01195103</nct_id>
  </id_info>
  <brief_title>Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery</brief_title>
  <official_title>A Prospective Randomized Study to Assess the Efficacy and Safety of Bolus-dose Lusedra (Fospropofol Disodium) 6.5 mg/kg or 10 mg/kg Versus a Placebo (With Midazolam Rescue) for Minimal-to-moderate Sedation in Patients Undergoing Procedural Sedation for Regional Anesthesia Blocks Prior to Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      How does Lusedra compare with current standard of care (midazolam) for minimal to moderate
      sedation for regional anesthesia blocks prior to orthopedic surgery?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study overall is aimed at establishing the superiority of a single intravenous bolus-dose
      of Lusedra for routine use in preoperative regional blocks that avoids deeper levels of
      sedation and increased risk of nerve damage in an over-sedated individual. The shorter
      half-life of Lusedra should also demonstrate a superior recovery profile compared to
      midazolam when used as a rescue comparator. While this study will only enroll patients
      undergoing regional blocks prior to orthopedic surgery, the clinical utility and value of the
      larger initial intravenous dosing for Lusedra may be evident for many different monitored
      anesthesia care anesthetic management situations requiring rapid and effective onset of
      effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding terminated by funding source.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sedation Within 4 Minutes</measure>
    <time_frame>approximately 4 minutes after administration of first bolus of study drug</time_frame>
    <description>Percentage of patients achieving a Modified Observer's Assessment of Alertness/Sedation Scale score less than or equal to 4, and the block procedure initiated, within 4 minutes of the administration of the first bolus of study drug. The Modified Observer's Assessment of Alertness/Sedation Scale ranges from 0 (does not respond to deep stimulus) to 6 (agitated). The score of 4 equals &quot;lethargic response to name spoken in normal tone.&quot;</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Procedural Sedation</condition>
  <condition>Regional Anesthesia Block</condition>
  <condition>Orthopedic Surgery</condition>
  <arm_group>
    <arm_group_label>10 mg/kg Lusedra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg Lusedra initial bolus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.5 mg/kg Lusedra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6.5 mg/kg Lusedra initial bolus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo initial bolus with dose of midazolam based on patient's weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fospropofol disodium</intervention_name>
    <description>10 mg/kg bolus</description>
    <arm_group_label>10 mg/kg Lusedra</arm_group_label>
    <other_name>Lusedra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fospropofol disodium</intervention_name>
    <description>6.5 mg/kg bolus</description>
    <arm_group_label>6.5 mg/kg Lusedra</arm_group_label>
    <other_name>Lusedra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Midazolam</intervention_name>
    <description>Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients &lt;60 kg; 1.5 mg for patients ≥60 kg to &lt;90 kg; or 2 mg for patients ≥90 kg</description>
    <arm_group_label>Placebo + Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients &lt;60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.</description>
    <arm_group_label>10 mg/kg Lusedra</arm_group_label>
    <arm_group_label>6.5 mg/kg Lusedra</arm_group_label>
    <arm_group_label>Placebo + Midazolam</arm_group_label>
    <other_name>Fentanyl Citrate</other_name>
    <other_name>Sublimaze</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing elective orthopedic surgery

          -  With a regional block prior to surgery

          -  Able to consent and complete the assessments and procedures

          -  If female, must be surgically sterile, postmenopausal, or not pregnant or lactating
             and using an acceptable method of birth control for at least 1 month prior to surgery
             with a negative urine pregnancy test at screening

          -  American Society of Anesthesiologists Physical Classification System status category
             P1 to P4

        Exclusion Criteria:

          -  History of allergic reaction or hypersensitivity to any anesthetic agent, opioid, or
             benzodiazepine

          -  Fentanyl citrate injection or midazolam hydrocholoride injection contraindicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John B Leslie, MD MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <results_first_submitted>February 27, 2012</results_first_submitted>
  <results_first_submitted_qc>March 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2012</results_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <name_title>John B Leslie MD MBA</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Procedural sedation</keyword>
  <keyword>Regional Anesthesia block</keyword>
  <keyword>Orthopedic surgery</keyword>
  <keyword>Lusedra</keyword>
  <keyword>Fospropofol disodium</keyword>
  <keyword>Midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fospropofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from Mayo Clinic, Arizona from March 1 - 11, 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>10 mg/kg Lusedra</title>
          <description>10 mg/kg Lusedra initial bolus</description>
        </group>
        <group group_id="P2">
          <title>6.5 mg/kg Lusedra</title>
          <description>6.5 mg/kg Lusedra initial bolus</description>
        </group>
        <group group_id="P3">
          <title>Placebo + Midazolam</title>
          <description>Placebo initial bolus with dose of midazolam based on patient's weight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5">One patient withdrew after randomization but before received study drug.</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mg/kg Lusedra</title>
          <description>10 mg/kg Lusedra initial bolus</description>
        </group>
        <group group_id="B2">
          <title>6.5 mg/kg Lusedra</title>
          <description>6.5 mg/kg Lusedra initial bolus</description>
        </group>
        <group group_id="B3">
          <title>Placebo + Midazolam</title>
          <description>Placebo initial bolus with dose of midazolam based on patient's weight</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="7.0"/>
                    <measurement group_id="B2" value="71.5" spread="4.3"/>
                    <measurement group_id="B3" value="72" spread="12"/>
                    <measurement group_id="B4" value="72.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Sedation Within 4 Minutes</title>
        <description>Percentage of patients achieving a Modified Observer's Assessment of Alertness/Sedation Scale score less than or equal to 4, and the block procedure initiated, within 4 minutes of the administration of the first bolus of study drug. The Modified Observer's Assessment of Alertness/Sedation Scale ranges from 0 (does not respond to deep stimulus) to 6 (agitated). The score of 4 equals &quot;lethargic response to name spoken in normal tone.&quot;</description>
        <time_frame>approximately 4 minutes after administration of first bolus of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 mg/kg Lusedra</title>
            <description>10 mg/kg Lusedra initial bolus</description>
          </group>
          <group group_id="O2">
            <title>6.5 mg/kg Lusedra</title>
            <description>6.5 mg/kg Lusedra initial bolus</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Midazolam</title>
            <description>Placebo initial bolus with dose of midazolam based on patient's weight</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sedation Within 4 Minutes</title>
          <description>Percentage of patients achieving a Modified Observer's Assessment of Alertness/Sedation Scale score less than or equal to 4, and the block procedure initiated, within 4 minutes of the administration of the first bolus of study drug. The Modified Observer's Assessment of Alertness/Sedation Scale ranges from 0 (does not respond to deep stimulus) to 6 (agitated). The score of 4 equals &quot;lethargic response to name spoken in normal tone.&quot;</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed for adverse events from the time of drug administration until entry into the operating room. Patients were sedated again for the surgery. We only studied the first sedation.</time_frame>
      <desc>No adverse event data were collected for the patient who withdrew prior to receiving study drug, so that patient was not included in the assessment of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>10 mg/kg Lusedra</title>
          <description>10 mg/kg Lusedra initial bolus</description>
        </group>
        <group group_id="E2">
          <title>6.5 mg/kg Lusedra</title>
          <description>6.5 mg/kg Lusedra initial bolus</description>
        </group>
        <group group_id="E3">
          <title>Placebo + Midazolam</title>
          <description>Placebo initial bolus with dose of midazolam based on patient's weight</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>deep sedation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>delayed recovery from sedation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>puritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early because funding was terminated by the funding source.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John B Leslie MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-301-8000</phone>
      <email>leslie.john@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

